HRP20160362T1 - Antigeni pripravak protiv bakterija iz roda mycobacterium - Google Patents
Antigeni pripravak protiv bakterija iz roda mycobacterium Download PDFInfo
- Publication number
- HRP20160362T1 HRP20160362T1 HRP20160362TT HRP20160362T HRP20160362T1 HR P20160362 T1 HRP20160362 T1 HR P20160362T1 HR P20160362T T HRP20160362T T HR P20160362TT HR P20160362 T HRP20160362 T HR P20160362T HR P20160362 T1 HRP20160362 T1 HR P20160362T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation according
- immunogenic preparation
- immunogenic
- intended
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Claims (23)
1. Imunogeni pripravak koji sadrži antigen povezan s M72, naznačen time što antigen povezan s M72 sadrži slijed koji je najmanje 90% istovjetan SEQ ID No: 1, pH navedenog pripravka je u rasponu od 7,0 do 9,0, a vodljivost pripravka je 5 mS/cm ili manja.
2. Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što je vodljivost pripravka 4 mS/cm ili manja.
3. Imunogeni pripravak u skladu s patentnim zahtjevom 2, naznačen time što je vodljivost pripravka 3 mS/cm ili manja.
4. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je koncentracija soli u navedenom pripravku 40 mM ili manja.
5. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što dodatno sadrži neionsko sredstvo za toničnost.
6. Imunogeni pripravak u skladu s patentnim zahtjevom 5, naznačen time što je neionsko sredstvo za toničnost poliol.
7. Imunogeni pripravak u skladu s patentnim zahtjevom 6, naznačen time što je poliol sorbitol i što je koncentracija sorbitola između otprilike 4 i otprilike 6% (tež./vol.).
8. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je koncentracija saharoze između otprilike 4 i otprilike 6% (tež./vol.).
9. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što dodatno sadrži jedan ili više imunostimulansa.
10. Imunogeni pripravak u skladu s patentnim zahtjevom 9, naznačen time što imunogeni pripravak sadrži QS21.
11. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 9 ili 10, naznačen time što imunogeni pripravak sadrži 3-de-O-acilirani monofosforilirani lipid A.
12. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je osmolalnost od 250 do 750 mOsm/kg.
13. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što se pripravak daje u obliku jedinične doze koja se kreće između 50 µl i 1 ml.
14. Imunogeni pripravak u skladu s patentnim zahtjevom 13, naznačen time što jedinična doza sadrži 5 do 50 µg proteina povezanog s M72.
15. Imunogeni pripravak u skladu s patentnim zahtjevom 13 ili 14, naznačen time što je jedinična doza doza namijenjena čovjeku i sadrži između 1 i 100 µg 3D-MPL.
16. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 13 to 15, naznačen time što je jedinična doza doza namijenjena čovjeku i sadrži između 1 i 100 µg QS21.
17. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 16, naznačen time što je pH navedenog pripravka u rasponu od 7,5 do 8,5.
18. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 17, naznačen time što antigen povezan s M72 ima aminokiselinski slijed sa SEQ ID No: 3.
19. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 17, naznačen time što antigen povezan s M72 ima slijed koji je najmanje 90% istovjetan SEQ ID No: 1.
20. Imunogeni pripravak u skladu s patentnim zahtjevom 19, naznačen time što antigen povezan s M72 ima aminokiselinski slijed sa SEQ ID No: 3.
21. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 20, naznačen time što je namijenjen upotrebi u medicini.
22. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 21, naznačen time što je namijenjen upotrebi u postupku profilakse, liječenja ili ublažavanja infekcije mikobakterijama.
23. Imunogeni pripravak, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 21 ili 22, naznačen time što je namijenjen primjeni na čovjeku.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42272310P | 2010-12-14 | 2010-12-14 | |
| EP11799673.6A EP2651437B1 (en) | 2010-12-14 | 2011-12-14 | Mycobacterium antigenic composition |
| PCT/EP2011/072816 WO2012080369A1 (en) | 2010-12-14 | 2011-12-14 | Mycobacterium antigenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160362T1 true HRP20160362T1 (hr) | 2016-05-06 |
Family
ID=45346501
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160362TT HRP20160362T1 (hr) | 2010-12-14 | 2011-12-14 | Antigeni pripravak protiv bakterija iz roda mycobacterium |
| HRP20160606TT HRP20160606T1 (hr) | 2010-12-14 | 2011-12-14 | Pripravak mikrobakterijskih antigena |
| HRP20191843TT HRP20191843T1 (hr) | 2010-12-14 | 2019-10-11 | Mikobakterijski antigenski pripravak |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160606TT HRP20160606T1 (hr) | 2010-12-14 | 2011-12-14 | Pripravak mikrobakterijskih antigena |
| HRP20191843TT HRP20191843T1 (hr) | 2010-12-14 | 2019-10-11 | Mikobakterijski antigenski pripravak |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US9730992B2 (hr) |
| EP (4) | EP2651436B1 (hr) |
| JP (2) | JP5951633B2 (hr) |
| KR (3) | KR20190022897A (hr) |
| CN (4) | CN106822882A (hr) |
| AR (1) | AR084285A1 (hr) |
| AU (2) | AU2011343368C1 (hr) |
| BR (2) | BR112013014598A2 (hr) |
| CA (2) | CA2819298A1 (hr) |
| CO (2) | CO6751288A2 (hr) |
| CY (1) | CY1122187T1 (hr) |
| DK (3) | DK2651436T3 (hr) |
| EA (2) | EA027504B1 (hr) |
| ES (3) | ES2748651T3 (hr) |
| HR (3) | HRP20160362T1 (hr) |
| HU (3) | HUE027932T2 (hr) |
| IL (2) | IL226450A0 (hr) |
| LT (1) | LT3023106T (hr) |
| ME (1) | ME02380B (hr) |
| MX (2) | MX344706B (hr) |
| MY (1) | MY161412A (hr) |
| PH (2) | PH12013501204A1 (hr) |
| PL (3) | PL2651436T3 (hr) |
| PT (2) | PT2651436E (hr) |
| RS (1) | RS54687B1 (hr) |
| SG (2) | SG190937A1 (hr) |
| SI (3) | SI3023106T1 (hr) |
| SM (1) | SMT201600118B (hr) |
| TW (1) | TW201305192A (hr) |
| UA (2) | UA110806C2 (hr) |
| UY (1) | UY33802A (hr) |
| WO (2) | WO2012080369A1 (hr) |
| ZA (2) | ZA201304015B (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2524572T3 (es) | 2005-04-29 | 2014-12-10 | Glaxosmithkline Biologicals S.A. | Procedimiento novedoso de prevención o tratamiento de infección por M. tuberculosis |
| HUE027932T2 (en) | 2010-12-14 | 2016-11-28 | Glaxosmithkline Biologicals Sa | Mycobacterium antigenic composition |
| CN103796640A (zh) * | 2011-01-04 | 2014-05-14 | 阿尔西维尔法尔玛公司 | 适于治疗或预防结核的脂质体制剂 |
| IN2014MN01594A (hr) | 2012-01-12 | 2015-05-08 | Archivel Farma Sl | |
| US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| KR102447958B1 (ko) | 2014-04-23 | 2022-09-27 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 치료용 면역 세포 집단의 단리, 배양 및 유전자 조작 방법 |
| GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| GB201522068D0 (en) | 2015-12-15 | 2016-01-27 | Glaxosmithkline Biolog Sa | Dried composition |
| ES2988600T3 (es) | 2016-12-07 | 2024-11-21 | Glaxosmithkline Biologicals Sa | Proceso para elaborar una composición de liposoma que comprende una saponina |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| GB201707700D0 (en) * | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
| MX2019014319A (es) | 2017-05-30 | 2020-02-07 | Glaxosmithkline Biologicals Sa | Procedimiento para fabricar un adyuvante. |
| EP3717001A1 (en) | 2017-12-01 | 2020-10-07 | GlaxoSmithKline Biologicals S.A. | Saponin purification |
| RU2728976C2 (ru) * | 2018-03-22 | 2020-08-03 | Зули Холдингз, Лтд. | Липосомный состав и его получение |
| US20210292395A1 (en) | 2018-07-31 | 2021-09-23 | Glaxosmithkline Biologicals Sa | Antigen purification method |
| EP3886901A1 (en) | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
| US20220235095A1 (en) | 2019-06-05 | 2022-07-28 | Glaxosmithkline Biologicals Sa | Saponin purification |
| EP3777884A1 (en) | 2019-08-15 | 2021-02-17 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| CN114466659A (zh) | 2019-09-09 | 2022-05-10 | 葛兰素史克生物有限公司 | 免疫治疗组合物 |
| CA3161857A1 (en) | 2019-11-22 | 2021-05-27 | Glaxosmithkline Biologicals Sa | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
| JP2023524136A (ja) | 2020-05-05 | 2023-06-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | マイクロ流体混合デバイス及び使用方法 |
| EP4161570A1 (en) | 2020-06-05 | 2023-04-12 | GlaxoSmithKline Biologicals S.A. | Modified betacoronavirus spike proteins |
| US20240026407A1 (en) | 2020-12-09 | 2024-01-25 | Glaxosmithkline Biologicals Sa | Modification of saponins |
| CN114034860A (zh) * | 2021-11-01 | 2022-02-11 | 宁夏大学 | 一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒 |
| EP4540401A1 (en) | 2022-06-15 | 2025-04-23 | GlaxoSmithKline Biologicals S.A. | Enzymatic modification of saponins |
| CN116120411B (zh) * | 2022-12-07 | 2024-04-12 | 中国疾病预防控制中心传染病预防控制所 | 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DE69015222T2 (de) | 1989-02-04 | 1995-05-04 | Akzo Nv | Tocole als Impfstoffadjuvans. |
| ES2162139T5 (es) | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
| ATE328890T1 (de) | 1994-07-15 | 2006-06-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| EP2154248B1 (en) | 1995-09-01 | 2011-10-26 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| ATE252640T1 (de) | 1995-09-01 | 2003-11-15 | Corixa Corp | Verbindungen zur immunotherapie und diagnose von tuberkulose |
| US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
| GB9619613D0 (en) | 1996-09-19 | 1996-10-30 | Breed Automotive Tech | An inflatable restraint for a vehicle |
| EP0859366A1 (en) | 1997-02-12 | 1998-08-19 | STMicroelectronics S.r.l. | Associative memory device with optimized occupation, particularly for the recognition of words |
| DK0973546T3 (da) * | 1997-04-08 | 2004-06-28 | Merck & Co Inc | Stabiliserede formuleringer med human papillomavirus |
| US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| DE19803453A1 (de) * | 1998-01-30 | 1999-08-12 | Boehringer Ingelheim Int | Vakzine |
| KR100797876B1 (ko) | 1998-04-07 | 2008-01-24 | 코릭사 코포레이션 | 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도 |
| NZ506603A (en) * | 1998-04-09 | 2002-10-25 | Smithkline Beecham Biolog S | Adjuvant compositions comprising polyoxyethylene ether or polyoxyethylene ester |
| US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| CA2386841A1 (en) * | 1999-10-07 | 2001-04-12 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| WO2001098460A2 (en) | 2000-06-20 | 2001-12-27 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| CN1449293B (zh) | 2000-06-29 | 2012-08-22 | 史密丝克莱恩比彻姆生物有限公司 | 多价疫苗组合物 |
| WO2003070187A2 (en) | 2002-02-15 | 2003-08-28 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| GB0411411D0 (en) | 2004-05-21 | 2004-06-23 | Glaxosmithkline Biolog Sa | Vaccines |
| ES2524572T3 (es) * | 2005-04-29 | 2014-12-10 | Glaxosmithkline Biologicals S.A. | Procedimiento novedoso de prevención o tratamiento de infección por M. tuberculosis |
| US9297803B2 (en) * | 2006-11-01 | 2016-03-29 | Immport Therapeutics, Inc. | Compositions and methods for immunodominant antigens |
| CL2008001491A1 (es) * | 2007-05-24 | 2008-11-28 | Glaxosmithkline Biolog Sa | Composicion liofilizada que comprende uno o mas antigenos y un agonista del receptor de tipo toll 9 (tlr9); y procedimiento de preparacion. |
| TWI629064B (zh) * | 2007-11-30 | 2018-07-11 | 艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| KR100955470B1 (ko) | 2008-01-09 | 2010-04-30 | 대한민국(관리부서 질병관리본부장) | 탄저 방어 항원의 제조 방법 |
| WO2009111874A1 (en) | 2008-03-11 | 2009-09-17 | The Royal Institution For The Advancement Of Learning/ Mcgiil University | Low-temperature wafer level processing for mems devices |
| GB0910045D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| GB0910046D0 (en) * | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
| GB201008512D0 (en) | 2010-05-21 | 2010-07-07 | Health Prot Agency | Mycobacterial antigen composition |
| IT1400834B1 (it) | 2010-07-07 | 2013-07-02 | Aero Sekur S P A | Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili. |
| HUE027932T2 (en) * | 2010-12-14 | 2016-11-28 | Glaxosmithkline Biologicals Sa | Mycobacterium antigenic composition |
| GB201400819D0 (en) | 2014-01-17 | 2014-03-05 | Sec Dep For Health The | Mycobacterial antigen composition |
-
2011
- 2011-12-14 HU HUE11799673A patent/HUE027932T2/en unknown
- 2011-12-14 LT LT15201196T patent/LT3023106T/lt unknown
- 2011-12-14 CN CN201610883668.4A patent/CN106822882A/zh active Pending
- 2011-12-14 AU AU2011343368A patent/AU2011343368C1/en not_active Ceased
- 2011-12-14 RS RS20160225A patent/RS54687B1/en unknown
- 2011-12-14 WO PCT/EP2011/072816 patent/WO2012080369A1/en active Application Filing
- 2011-12-14 KR KR1020197004934A patent/KR20190022897A/ko not_active Ceased
- 2011-12-14 UA UAA201306356A patent/UA110806C2/uk unknown
- 2011-12-14 CN CN201710066847.3A patent/CN106822883A/zh active Pending
- 2011-12-14 US US13/993,386 patent/US9730992B2/en active Active
- 2011-12-14 TW TW100146325A patent/TW201305192A/zh unknown
- 2011-12-14 MY MYPI2013700989A patent/MY161412A/en unknown
- 2011-12-14 EA EA201390630A patent/EA027504B1/ru not_active IP Right Cessation
- 2011-12-14 CN CN201180060222.7A patent/CN103249431B/zh active Active
- 2011-12-14 KR KR1020137018060A patent/KR101951894B1/ko active Active
- 2011-12-14 ES ES15201196T patent/ES2748651T3/es active Active
- 2011-12-14 PL PL11794778.8T patent/PL2651436T3/pl unknown
- 2011-12-14 BR BR112013014598A patent/BR112013014598A2/pt not_active Application Discontinuation
- 2011-12-14 KR KR1020137018059A patent/KR20140029376A/ko not_active Withdrawn
- 2011-12-14 SI SI201131805T patent/SI3023106T1/sl unknown
- 2011-12-14 EP EP11794778.8A patent/EP2651436B1/en active Active
- 2011-12-14 SG SG2013041918A patent/SG190937A1/en unknown
- 2011-12-14 CN CN201180060489.6A patent/CN103260642B/zh active Active
- 2011-12-14 EP EP11799673.6A patent/EP2651437B1/en active Active
- 2011-12-14 ES ES11794778.8T patent/ES2574403T3/es active Active
- 2011-12-14 SI SI201130787A patent/SI2651437T1/sl unknown
- 2011-12-14 BR BR112013014599A patent/BR112013014599A2/pt not_active Application Discontinuation
- 2011-12-14 HR HRP20160362TT patent/HRP20160362T1/hr unknown
- 2011-12-14 AR ARP110104678A patent/AR084285A1/es unknown
- 2011-12-14 ME MEP-2016-60A patent/ME02380B/me unknown
- 2011-12-14 DK DK11794778.8T patent/DK2651436T3/da active
- 2011-12-14 WO PCT/EP2011/072817 patent/WO2012080370A1/en active Application Filing
- 2011-12-14 CA CA2819298A patent/CA2819298A1/en not_active Abandoned
- 2011-12-14 PT PT117947788T patent/PT2651436E/pt unknown
- 2011-12-14 PH PH1/2013/501204A patent/PH12013501204A1/en unknown
- 2011-12-14 EP EP19188906.2A patent/EP3593813A1/en not_active Withdrawn
- 2011-12-14 MX MX2013006818A patent/MX344706B/es active IP Right Grant
- 2011-12-14 MX MX2013006819A patent/MX344280B/es active IP Right Grant
- 2011-12-14 CA CA2819297A patent/CA2819297A1/en not_active Abandoned
- 2011-12-14 JP JP2013543775A patent/JP5951633B2/ja active Active
- 2011-12-14 EP EP15201196.1A patent/EP3023106B1/en active Active
- 2011-12-14 DK DK15201196.1T patent/DK3023106T3/da active
- 2011-12-14 PL PL11799673T patent/PL2651437T3/pl unknown
- 2011-12-14 PH PH1/2013/501203A patent/PH12013501203A1/en unknown
- 2011-12-14 HU HUE15201196A patent/HUE045766T2/hu unknown
- 2011-12-14 UY UY0001033802A patent/UY33802A/es not_active Application Discontinuation
- 2011-12-14 DK DK11799673.6T patent/DK2651437T3/en active
- 2011-12-14 SG SG2013041793A patent/SG190731A1/en unknown
- 2011-12-14 PL PL15201196T patent/PL3023106T3/pl unknown
- 2011-12-14 EA EA201390631A patent/EA027920B1/ru not_active IP Right Cessation
- 2011-12-14 HU HUE11794778A patent/HUE028452T2/en unknown
- 2011-12-14 JP JP2013543776A patent/JP5951634B2/ja active Active
- 2011-12-14 UA UAA201306355A patent/UA110118C2/uk unknown
- 2011-12-14 US US13/993,736 patent/US9352030B2/en active Active
- 2011-12-14 HR HRP20160606TT patent/HRP20160606T1/hr unknown
- 2011-12-14 PT PT152011961T patent/PT3023106T/pt unknown
- 2011-12-14 AU AU2011343367A patent/AU2011343367B2/en not_active Ceased
- 2011-12-14 ES ES11799673.6T patent/ES2567190T3/es active Active
- 2011-12-14 SI SI201130859A patent/SI2651436T1/sl unknown
-
2013
- 2013-05-20 IL IL226450A patent/IL226450A0/en unknown
- 2013-05-20 IL IL226448A patent/IL226448A/en active IP Right Grant
- 2013-05-31 ZA ZA2013/04015A patent/ZA201304015B/en unknown
- 2013-05-31 ZA ZA2013/04014A patent/ZA201304014B/en unknown
- 2013-06-19 CO CO13146307A patent/CO6751288A2/es unknown
- 2013-06-19 CO CO13146289A patent/CO6751287A2/es unknown
-
2016
- 2016-04-18 US US15/131,422 patent/US20160220656A1/en not_active Abandoned
- 2016-04-22 SM SM201600118T patent/SMT201600118B/it unknown
-
2017
- 2017-07-06 US US15/643,084 patent/US10441648B2/en active Active
-
2019
- 2019-02-08 US US16/270,887 patent/US20190183998A1/en not_active Abandoned
- 2019-10-11 HR HRP20191843TT patent/HRP20191843T1/hr unknown
- 2019-10-18 CY CY20191101093T patent/CY1122187T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160362T1 (hr) | Antigeni pripravak protiv bakterija iz roda mycobacterium | |
| HRP20191299T1 (hr) | Formulacije protutijela | |
| MX2015015152A (es) | Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13. | |
| AR076748A1 (es) | Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteinas. metodo de tratamiento | |
| PE20130579A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa | |
| NZ629261A (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
| CL2013002148A1 (es) | Composición farmacéutica vaginal sólida efervescente que comprende un sistema ácido-base, una mezcla de celulosa microcristalina y arabinogalactano y al menos una cepa bacteriana probiótica; y su uso para el tratamiento de infecciones vaginales tales como vaginitis, candidiasis, gonorrea y úlcera venérea. | |
| HRP20171256T1 (hr) | Farmaceutski pripravci karbetocina | |
| PE20141159A1 (es) | Metodos para tratar o prevenir trastornos relacionados con el colesterol | |
| BR112012018951C8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| AR094202A1 (es) | Productos para el cuidado oral que contienen un complejo de zinc tetrabasico-acido amino-haluro, metodo | |
| HRP20140792T1 (hr) | Adjuvantni pripravci koji sadrže neionsko izotoniäśno sredstvo | |
| AR086651A1 (es) | Dentifrico de ion metalico con bajo contenido de agua | |
| NZ602498A (en) | Protein formulations and methods of making same | |
| BR112014022451A2 (pt) | lipídios aminoácido vetorizadores, sistema veículo, seu uso, e composição farmacêutica | |
| NZ630885A (en) | Antibody formulation | |
| RU2012139181A (ru) | Стабильная композиция, содержащая антитело | |
| RS54822B1 (sr) | Kompozicija i formulacija koja obuhvata rekombinovanu humanu iduronat-2-sulfatazu i postupak za njeno dobijanje | |
| AR082257A1 (es) | Composicion de inmunoglobulinas humanas concentradas, procedimiento | |
| AR100268A1 (es) | Formulación líquida que comprende compuesto neutralizante de gm-csf | |
| US20060008466A1 (en) | Methods for treating and preventing microbial infections | |
| BR112013019513A2 (pt) | métodos para o tratamento de úlceras diabéticas do pé | |
| EA201591663A1 (ru) | Бесклеточная противококлюшная вакцина | |
| PH12015502005B1 (en) | New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof |